Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Salamero, Olga"" wg kryterium: Autor


Wyświetlanie 1-8 z 8
Tytuł:
Prognostic impact of micromegakaryocytes in primary myelodysplastic syndromes.
Autorzy:
Saumell S; Department of Hematology, Experimental Hematology Unit, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Barcelona, Spain.
Fernández-Serrano M; Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Barcelona, Spain.; Lymphoma Translational Group, Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
Mesa A; Department of Hematology, Experimental Hematology Unit, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Barcelona, Spain.
López-Cadenas F; Department of Hematology, University Hospital of Salamanca, Salamanca, Spain.
Arenillas L; Laboratory of Cytology, Department of Pathology, GRETNHE, IMIM Hospital del Mar Research Institute, Barcelona, Spain.
Alfonso A; Clínica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain.
Montoro MJ; Department of Hematology, Experimental Hematology Unit, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Barcelona, Spain.
Molero A; Department of Hematology, Experimental Hematology Unit, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Barcelona, Spain.
Leoz P; Department of Hematology, University Hospital of Salamanca, Salamanca, Spain.
Riego V; Clínica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain.
Gallur L; Department of Hematology, Experimental Hematology Unit, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Barcelona, Spain.
Salamero O; Department of Hematology, Experimental Hematology Unit, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Barcelona, Spain.
Navarrete M; Department of Hematology, Experimental Hematology Unit, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Barcelona, Spain.
Tazón-Vega B; Department of Hematology, Experimental Hematology Unit, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Barcelona, Spain.
Ortega M; Department of Hematology, Experimental Hematology Unit, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Barcelona, Spain.
Reig Ò; Medical Oncology Department, Hospital Clínic, Translational Genomics and Targeted Therapeutics in Solid Tumors Group (IDIBAPS), Barcelona, Spain.
Roué G; Department of Hematology, Experimental Hematology Unit, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Barcelona, Spain.; Lymphoma Translational Group, Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
Calvo X; Laboratory of Cytology, Department of Pathology, GRETNHE, IMIM Hospital del Mar Research Institute, Barcelona, Spain.
Prosper F; Clínica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain.
Díez-Campelo M; Department of Hematology, University Hospital of Salamanca, Salamanca, Spain.
Valcárcel D; Department of Hematology, Experimental Hematology Unit, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Barcelona, Spain.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 May; Vol. 63 (5), pp. 1227-1235. Date of Electronic Publication: 2021 Dec 31.
Typ publikacji:
Journal Article
MeSH Terms:
Leukemia, Myeloid, Acute*/diagnosis
Myelodysplastic Syndromes*/diagnosis
Adult ; Humans ; Prognosis ; Retrospective Studies ; Risk Factors
Czasopismo naukowe
Tytuł:
Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis.
Autorzy:
Fox ML; Department of Hematology, Hospital Universitari Vall d'Hebron, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain.
García-Cadenas I; Department of Hematology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute (IIB Sant-Pau), Barcelona, Spain.; José Carreras Leukemia Research Institute, Autonomous University of Barcelona (UAB), Barcelona, Spain.
Pérez AM; Department of Hematology, Hospital Clínico Universitario- INCLIVA. University of Valencia, Valencia, Spain.
Villacampa G; Oncology Data Science (ODysSey) Group, Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Piñana JL; Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain - CIBERONC, Instituto Carlos III, Madrid, Spain.
Ortí G; Department of Hematology, Hospital Universitari Vall d'Hebron, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Montoro J; Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain - CIBERONC, Instituto Carlos III, Madrid, Spain.
Roldán E; Department of Hematology, Hospital Universitari Vall d'Hebron, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Bosch Vilaseca A; Department of Hematology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute (IIB Sant-Pau), Barcelona, Spain.; José Carreras Leukemia Research Institute, Autonomous University of Barcelona (UAB), Barcelona, Spain.
Martino R; Department of Hematology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute (IIB Sant-Pau), Barcelona, Spain.; José Carreras Leukemia Research Institute, Autonomous University of Barcelona (UAB), Barcelona, Spain.
Salamero O; Department of Hematology, Hospital Universitari Vall d'Hebron, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Saavedra S; Department of Hematology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute (IIB Sant-Pau), Barcelona, Spain.; José Carreras Leukemia Research Institute, Autonomous University of Barcelona (UAB), Barcelona, Spain.
Hernandez-Boluda JC; Department of Hematology, Hospital Clínico Universitario- INCLIVA. University of Valencia, Valencia, Spain.
Esquirol A; Department of Hematology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute (IIB Sant-Pau), Barcelona, Spain.; José Carreras Leukemia Research Institute, Autonomous University of Barcelona (UAB), Barcelona, Spain.
Sierra J; Department of Hematology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute (IIB Sant-Pau), Barcelona, Spain.; José Carreras Leukemia Research Institute, Autonomous University of Barcelona (UAB), Barcelona, Spain.
Sanz J; Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain - CIBERONC, Instituto Carlos III, Madrid, Spain.
Solano C; Department of Hematology, Hospital Clínico Universitario- INCLIVA. University of Valencia, Valencia, Spain.
Bosch F; Department of Hematology, Hospital Universitari Vall d'Hebron, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Barba P; Department of Hematology, Hospital Universitari Vall d'Hebron, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Valcarcel D; Department of Hematology, Hospital Universitari Vall d'Hebron, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2020 Aug; Vol. 61 (8), pp. 1823-1832. Date of Electronic Publication: 2020 Jul 11.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Graft vs Host Disease*/etiology
Graft vs Host Disease*/prevention & control
Hematopoietic Stem Cell Transplantation*/adverse effects
Busulfan ; Feasibility Studies ; Humans ; Retrospective Studies ; Sirolimus ; Tacrolimus ; Thiotepa ; Transplantation Conditioning ; Vidarabine/analogs & derivatives
Czasopismo naukowe
Tytuł:
Real life outcomes of patients aged ≥75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry.
Autorzy:
Salamero O; UAB-Medicine Department, Hospital Universitario Vall d'Hebron, VHIO, Barcelona, Spain.
Martínez-Cuadrón D; Hospital Universitari i Politècnic La Fe, Valencia, Spain.; CIBERONC, Instituto Carlos III, Madrid, Spain.
Sobas M; Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland.
Benavente C; Hospital Clínico San Carlos, Madrid, Spain.
Vives S; ICO-Hospital Universitari Germans Trias i Pujol, Jose Carreras Research Institute, Badalona, Spain.
De la Serna J; Hospital 12 de Octubre, Madrid, Spain.
Pérez-Encinas M; Hospital Clínico Universitario, Santiago de Compostela, Spain.
Escoda L; Hospital Joan XXIII, Tarragona, Spain.
Gil C; Hospital General de Alicante, Alicante, Spain.
Brunet S; Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Ramos F; Hospital Universitario de León, León, Spain.
Esteve J; Hospital Clinic, Barcelona, Spain.
Amigo M; Hospital Morales Meseguer, Murcia, Spain.
Krsnik I; Hospital Puerta del Hierro, Madrid, Spain.
Manso F; Hospital General de Albacete, Albacete, Spain.
Arias J; Hospital Universitario Lucus Augusti, Lugo, Spain.
González-Campos J; Hospital Universitario Virgen del Rocío, Sevilla, Spain.
Serrano J; Hospital Reina Sofía, Córdoba, Spain.
Oleksiuk J; Medical University of Bialystok, Bialystok, Poland.
Barrios M; Hospital Regional Universitario Carlos Haya, Málaga, Spain.
García-Boyero R; Hospital General de Castellón, Castellón, Spain.
Novo A; Hospital Universitari Son Espases, Palma, Spain.
Sanz MA; Hospital Universitari i Politècnic La Fe, Valencia, Spain.; CIBERONC, Instituto Carlos III, Madrid, Spain.
Montesinos P; Hospital Universitari i Politècnic La Fe, Valencia, Spain.; CIBERONC, Instituto Carlos III, Madrid, Spain.
Pokaż więcej
Corporate Authors:
PETHEMA and PALG Groups
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2019 Nov; Vol. 60 (11), pp. 2720-2732. Date of Electronic Publication: 2019 May 09.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Leukemia, Promyelocytic, Acute/*mortality
Neoplasm Recurrence, Local/*mortality
Registries/*statistics & numerical data
Aged ; Aged, 80 and over ; Cohort Studies ; Female ; Follow-Up Studies ; Humans ; Idarubicin/administration & dosage ; Leukemia, Promyelocytic, Acute/drug therapy ; Leukemia, Promyelocytic, Acute/pathology ; Male ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/pathology ; Remission Induction ; Survival Rate ; Treatment Outcome ; Tretinoin/administration & dosage
Czasopismo naukowe
Tytuł:
Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes.
Autorzy:
Montoro J; a Department of Hematology , University Hospital Vall d'Hebron, University Autònoma of Barcelona (UAB) , Spain.; b Experimental Hematology Unit , Vall d'Hebron Institute of Oncology (VHIO) , Barcelona , Spain.
Pomares H; c Department of Hematology , Institut Català d'Oncologia (ICO) - Hospitalet , Barcelona , Spain.
Villacampa G; d Oncology Data Science (ODysSey) Group , Vall d'Hebron Institute of Oncology (VHIO) , Barcelona , Spain.
Merchán B; a Department of Hematology , University Hospital Vall d'Hebron, University Autònoma of Barcelona (UAB) , Spain.; b Experimental Hematology Unit , Vall d'Hebron Institute of Oncology (VHIO) , Barcelona , Spain.
Molero A; a Department of Hematology , University Hospital Vall d'Hebron, University Autònoma of Barcelona (UAB) , Spain.; b Experimental Hematology Unit , Vall d'Hebron Institute of Oncology (VHIO) , Barcelona , Spain.
Alonso E; e Department of Pathology , Hospital Universitari de Bellvitge , Barcelona , Spain Hospitalet.
Gallur L; a Department of Hematology , University Hospital Vall d'Hebron, University Autònoma of Barcelona (UAB) , Spain.; b Experimental Hematology Unit , Vall d'Hebron Institute of Oncology (VHIO) , Barcelona , Spain.
Grau J; f Department of Laboratory Hematology , University Hospital Germans Trias i Pujol, Badalona, Spain. ICO Josep Carreras Leukemia Research Institute , Badalona , Spain.
Salamero O; a Department of Hematology , University Hospital Vall d'Hebron, University Autònoma of Barcelona (UAB) , Spain.; b Experimental Hematology Unit , Vall d'Hebron Institute of Oncology (VHIO) , Barcelona , Spain.
Roldán E; a Department of Hematology , University Hospital Vall d'Hebron, University Autònoma of Barcelona (UAB) , Spain.; b Experimental Hematology Unit , Vall d'Hebron Institute of Oncology (VHIO) , Barcelona , Spain.
Saumell S; a Department of Hematology , University Hospital Vall d'Hebron, University Autònoma of Barcelona (UAB) , Spain.; b Experimental Hematology Unit , Vall d'Hebron Institute of Oncology (VHIO) , Barcelona , Spain.
Ortega M; a Department of Hematology , University Hospital Vall d'Hebron, University Autònoma of Barcelona (UAB) , Spain.; b Experimental Hematology Unit , Vall d'Hebron Institute of Oncology (VHIO) , Barcelona , Spain.
Sureda A; c Department of Hematology , Institut Català d'Oncologia (ICO) - Hospitalet , Barcelona , Spain.
Bosch F; a Department of Hematology , University Hospital Vall d'Hebron, University Autònoma of Barcelona (UAB) , Spain.; b Experimental Hematology Unit , Vall d'Hebron Institute of Oncology (VHIO) , Barcelona , Spain.
Arnan M; c Department of Hematology , Institut Català d'Oncologia (ICO) - Hospitalet , Barcelona , Spain.
Valcárcel D; a Department of Hematology , University Hospital Vall d'Hebron, University Autònoma of Barcelona (UAB) , Spain.; b Experimental Hematology Unit , Vall d'Hebron Institute of Oncology (VHIO) , Barcelona , Spain.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2019 Jun; Vol. 60 (6), pp. 1522-1527. Date of Electronic Publication: 2018 Nov 30.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Models, Biological*
Patient Selection*
Clinical Decision-Making/*methods
Myelodysplastic Syndromes/*therapy
Adult ; Aged ; Aged, 80 and over ; Clinical Trials as Topic ; Female ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Myelodysplastic Syndromes/mortality ; Predictive Value of Tests ; Prognosis ; ROC Curve ; Reference Values ; Research Design ; Retrospective Studies ; Risk Assessment/methods ; Risk Factors ; Young Adult
Czasopismo naukowe
Tytuł:
Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy.
Autorzy:
Labrador J; a Hospital Universitario de Burgos , Burgos , Spain.
Luño E; b Department of Hematology , Hospital Universitario Central de Asturias , Oviedo , Spain.
Vellenga E; c University Medical Center Groningen , University of Groningen , Groningen , The Netherlands.
Brunet S; d Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau and Jose Carreras Leukemia Research Institutes , Universitat Autònoma de Barcelona , Barcelona , Spain.
González-Campos J; e Hospital Universitario Virgen del Rocío , Sevilla , Spain.
Chillón MC; f University Hospital of Salamanca-Instituto de Investigación Biomédica de Salamanca , Salamanca , Spain.; g CIBERONC, Instituto Carlos III , Madrid , Spain.
Holowiecka A; h Department of Haematology and BMT , Silesian Medical University , Katowice , Poland.
Esteve J; i Hospital Clinic , Barcelona , Spain.
Bergua J; j Hospital San Pedro de Alcántara , Cáceres , Spain.
González-Sanmiguel JD; k Hospital Insular , Las Palmas , Spain.
Gil C; l Hospital General de Alicante , Alicante , Spain.
Tormo M; m Hospital Clínico Universitario de Valencia , Valencia , Spain.
Salamero O; n Hospital Universitario Vall d´Hebron , Barcelona , Spain.
Manso F; o Hospital General , Albacete , Spain.
Fernández I; p Fundaleu , Buenos Aires , Argentina.
de laSerna J; q Hospital 12 de Octubre , Madrid , Spain.
Moreno MJ; r Hospital Virgen de la Victoria , Málaga , Spain.
Pérez-Encinas M; s Hospital Clínico Universitario , Santiago de Compostela , Spain.
Krsnik I; t Hospital Puerta de Hierro , Madrid , Spain.
Ribera JM; u ICO-Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukemia Research Institute , Universitat Autònoma de Barcelona , Barcelona , Spain.
Cervera J; v Hematology Department , Hospital Universitari i Politécnic La Fe , Valencia , Spain.
Calasanz MJ; g CIBERONC, Instituto Carlos III , Madrid , Spain.; w CIMA Lab Diagnostics , Pamplona , Spain.; x University of Navarra , Pamplona , Spain.
Boluda B; g CIBERONC, Instituto Carlos III , Madrid , Spain.; v Hematology Department , Hospital Universitari i Politécnic La Fe , Valencia , Spain.
Sobas M; y Department of Haematology, Blood Neoplasms and Bone Marrow Transplantation , Wroclaw Medical University , Wroclaw , Poland.
Lowenberg B; z Erasmus University Medical Center , Rotterdam , The Netherlands.
Sanz MA; g CIBERONC, Instituto Carlos III , Madrid , Spain.; v Hematology Department , Hospital Universitari i Politécnic La Fe , Valencia , Spain.; aa Department of Medicine , University of Valencia , Valencia , Spain.
Montesinos P; g CIBERONC, Instituto Carlos III , Madrid , Spain.; v Hematology Department , Hospital Universitari i Politécnic La Fe , Valencia , Spain.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2019 May; Vol. 60 (5), pp. 1146-1155. Date of Electronic Publication: 2018 Dec 11.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Abnormal Karyotype*
Chromosome Aberrations*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Arsenic Trioxide/*therapeutic use
Leukemia, Promyelocytic, Acute/*drug therapy
Leukemia, Promyelocytic, Acute/*genetics
Adolescent ; Adult ; Age Factors ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Arsenic Trioxide/administration & dosage ; Arsenic Trioxide/adverse effects ; Child ; Child, Preschool ; Cytogenetic Analysis ; Female ; Humans ; In Situ Hybridization, Fluorescence ; Leukemia, Promyelocytic, Acute/diagnosis ; Leukemia, Promyelocytic, Acute/mortality ; Leukocyte Count ; Male ; Middle Aged ; Prognosis ; Recurrence ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł:
An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens.
Autorzy:
Sobas M; a Department of Haematology , Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University , Poland.
Montesinos P; b Department of Medicine , University Hospital La Fe in Valencia , Spain.; c CIBERONC, Carlos III Institute , Madrid , Spain.
Boluda B; b Department of Medicine , University Hospital La Fe in Valencia , Spain.
Bernal T; d Central University Hospital in Asturias , Oviedo , Spain.
Vellenga E; e University Hospital , Groningen , The Netherlands.
Nomdedeu J; f University Hospital de la Santa Creu i Sant Paul in Barcelona (Hospital of the Holy Cross and Saint Paul), Universitat Autònoma de Barcelona , Barcelona , Spain.
González-Campos J; g University Hospital Virgen del Rocio in Sevilla , Spain.
Chillón M; c CIBERONC, Carlos III Institute , Madrid , Spain.; h University Hospital of Salamanca , Salamanca , Spain.
Holowiecka A; i Silesian Medical University , Katowice , Poland.
Esteve J; j Hospital Clinic in Barcelona , Spain.
Bergua J; k Hospital San Pedro in Alcántara , Cáceres , Spain.
González-Sanmiguel JD; l Insular University Hospital in Gran Canaria, Las Palmas de Gran Canaria , Spain.
Gil-Cortes C; m General Hospital in Alicante , Spain.
Tormo M; n University Hospital in Valencia , Spain.
Salamero O; o University Hospital Vall d´Hebron , Barcelona , Spain.
Manso F; p General Hospital in Albacete , Spain.
Fernández I; q Fundaleu , Buenos Aires , Argentina.
de la Serna J; r Hospital 12 de Octube in Madrid , Madrid , Spain x>/x>.
Moreno MJ; s Univeristy Hospital Virgen de la Victoria , Malaga , Spain.
Pérez-Encinas M; t University Hospital of Santiago de Compostela , Spain.
Krsnik I; u Hospital Puerta de Hierro , Madrid , Spain.
Ribera JM; v ICO University Hospital Germans Trias i Pujol; Jose Carreras Research Institute , Badalona , Spain.
Escoda L; w Hospital Joan XXIII , Tarragona , Spain.
Lowenberg B; x Erasmus University Medical Center , Rotterdam , The Netherlands.
Sanz MA; b Department of Medicine , University Hospital La Fe in Valencia , Spain.; c CIBERONC, Carlos III Institute , Madrid , Spain.
Pokaż więcej
Corporate Authors:
PETHEMA, HOVON, PALG, and GATLA cooperative groups
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2019 Apr; Vol. 60 (4), pp. 1030-1035. Date of Electronic Publication: 2018 Oct 15.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
CD56 Antigen/*metabolism
Leukemia, Promyelocytic, Acute/*drug therapy
Leukemia, Promyelocytic, Acute/*metabolism
Adolescent ; Adult ; Aged ; Anthracyclines/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; CD56 Antigen/genetics ; Child ; Child, Preschool ; Female ; Gene Expression ; Humans ; Kaplan-Meier Estimate ; Leukemia, Promyelocytic, Acute/diagnosis ; Leukemia, Promyelocytic, Acute/mortality ; Male ; Middle Aged ; Prognosis ; Recurrence ; Treatment Outcome ; Tretinoin/administration & dosage ; Young Adult
Czasopismo naukowe
Tytuł:
Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival.
Autorzy:
Guillem V; a Department of Hematology and Medical Oncology , Hospital Clínico Universitario INCLIVA Biomedical Research Institute , Valencia , Spain.
Calabuig M; a Department of Hematology and Medical Oncology , Hospital Clínico Universitario INCLIVA Biomedical Research Institute , Valencia , Spain.
Brunet S; b Department of Hematology , Hospital de Sant Pau, IIB Sant Pau and Jose Carreras Leukemia Research Institutes, Universidad Autónoma de Barcelona , Spain.
Esteve J; c Department of Hematology , Hospital Clínic, IDIBAPS , Barcelona , Spain.
Escoda L; d Department of Hematology , Hospital Universitari Joan XIII , Tarragona , Spain.
Gallardo D; e Department of Hematology , ICO Girona, Hospital Josep Trueta, IDIBGI Foundation , Girona , Spain.
Ribera JM; f Department of Hematology , ICO Badalona - Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autonoma de Barcelona , Badalona , Spain.
Queipo de Llano MP; g Department of Hematology , Hospital Virgen de la Victoria , Málaga , Spain.
Arnan M; h Department of Hematology , ICO - Hospital Duran i Reynals , Barcelona , Spain.
Pedro C; i Department of Hematology , Hospital del Mar, Parc de Salut Mar , Barcelona , Spain.
Amigo ML; j Department of Hematology , Hospital Morales Meseguer , Murcia , Spain.
Martí-Tutusaus JM; k Hospital Universitari Mútua Terrassa , Terrasa , Spain.
García-Guiñón A; l Department of Hematology , Hospital Universitari Arnau de Villanova , Lleida , Spain.
Bargay J; m Department of Hematology , Hospital Son Llatzer , Mallorca , Spain.
Sampol A; n Department of Hematology , University Hospital Son Espases, Instituto IDISPA , Palma de Mallorca , Spain.
Salamero O; o Department of Hematology , Hospital Vall d'Hebron , Barcelona , Spain.
Font L; p Department of Hematology , Hospital Verge de la Cinta , Tortosa , Spain.
Talarn C; c Department of Hematology , Hospital Clínic, IDIBAPS , Barcelona , Spain.
Hoyos M; b Department of Hematology , Hospital de Sant Pau, IIB Sant Pau and Jose Carreras Leukemia Research Institutes, Universidad Autónoma de Barcelona , Spain.
Díaz-Beyá M; c Department of Hematology , Hospital Clínic, IDIBAPS , Barcelona , Spain.
Garrido A; b Department of Hematology , Hospital de Sant Pau, IIB Sant Pau and Jose Carreras Leukemia Research Institutes, Universidad Autónoma de Barcelona , Spain.
Navarro B; a Department of Hematology and Medical Oncology , Hospital Clínico Universitario INCLIVA Biomedical Research Institute , Valencia , Spain.
Nomdédeu J; b Department of Hematology , Hospital de Sant Pau, IIB Sant Pau and Jose Carreras Leukemia Research Institutes, Universidad Autónoma de Barcelona , Spain.
Sierra J; b Department of Hematology , Hospital de Sant Pau, IIB Sant Pau and Jose Carreras Leukemia Research Institutes, Universidad Autónoma de Barcelona , Spain.
Tormo M; a Department of Hematology and Medical Oncology , Hospital Clínico Universitario INCLIVA Biomedical Research Institute , Valencia , Spain.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2018 Oct; Vol. 59 (10), pp. 2383-2393. Date of Electronic Publication: 2018 Jan 18.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Biomarkers, Tumor/*metabolism
Leukemia, Myeloid, Acute/*pathology
Myelodysplastic Syndromes/*pathology
Vascular Endothelial Growth Factor C/*metabolism
Adolescent ; Adult ; Aged ; Bone Marrow/pathology ; Chromosome Aberrations ; Female ; Humans ; Kaplan-Meier Estimate ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/mortality ; Male ; Middle Aged ; Myelodysplastic Syndromes/genetics ; Myelodysplastic Syndromes/mortality ; Neuropilin-1/metabolism ; Prognosis ; Vascular Endothelial Growth Factor Receptor-1/metabolism ; Vascular Endothelial Growth Factor Receptor-2/metabolism ; Young Adult
Czasopismo naukowe
Tytuł:
Autologous stem cell transplantation for patients with active Hodgkin's lymphoma: long-term outcome of 61 patients from a single institution.
Autorzy:
Martínez C; Department of Hematology, Institute of Hematology and Oncology, Institut d'Investigacions Biomèdiques August Pi I Sunyer IDIBAPS, Hospital Clínic, University of Barcelona, Barcelona, Spain. />Salamero O
Arenillas L
Duque J
López-Guillermo A
Rovira M
Urbano-Ispízua A
Fernández-Avilés F
Carreras E
Montserrat E
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2007 Oct; Vol. 48 (10), pp. 1968-75.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hematopoietic Stem Cell Transplantation/*methods
Hodgkin Disease/*immunology
Hodgkin Disease/*therapy
Adolescent ; Adult ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Prognosis ; Recurrence ; Remission Induction ; Time Factors ; Transplantation Conditioning ; Transplantation, Autologous/methods ; Treatment Outcome
Czasopismo naukowe
    Wyświetlanie 1-8 z 8

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies